Debby den Uyl
About
Debby den Uyl is a scholar working on Rheumatology, Hematology and Orthopedics and Sports Medicine.
According to data from OpenAlex, Debby den Uyl has authored 21 papers receiving a total of 770 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Rheumatology, 6 papers in Hematology and 5 papers in Orthopedics and Sports Medicine. Recurrent topics in Debby den Uyl's work include Rheumatoid Arthritis Research and Therapies (14 papers), Systemic Lupus Erythematosus Research (6 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Debby den Uyl is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (14 papers), Systemic Lupus Erythematosus Research (6 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Debby den Uyl collaborates with scholars based in Netherlands, United States and Vietnam. Debby den Uyl's co-authors include Willem F. Lems, Irene E. M. Bultink, Michael T. Nurmohamed, Hennie G. Raterman, L. van Tuyl, Maarten Boers, Alexandre E. Voskuyl, Marieke M. ter Wee, Ben A. C. Dijkmans and Dirkjan van Schaardenburg and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Annals of the Rheumatic Diseases and Bone.
In The Last Decade
Debby den Uyl
21 papers receiving 745 citations
Peers
Debby den Uyl
A. Krabben Netherlands
Chung‐Yuan Hsu Taiwan
Takeshi Nakatsue Japan
E. K. Li China
Laurence Lutteri Belgium
Gaël Mouterde France
Predrag Musikic Slovenia
Giusy Peluso Italy
Akinari Sekine Japan
Šárka Forejtová Czechia
Citations per year, relative to Debby den Uyl Debby den Uyl (= 1×)
peers
A. Krabben
Countries citing papers authored by Debby den Uyl
Since
Specialization
Citations
This map shows the geographic impact of Debby den Uyl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debby den Uyl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debby den Uyl more than expected).
Fields of papers citing papers by Debby den Uyl
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Debby den Uyl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debby den Uyl. The network helps show where Debby den Uyl may publish in the future.
Co-authorship network of co-authors of Debby den Uyl
This figure shows the co-authorship network connecting the top 25 collaborators of Debby den Uyl. A scholar is included among the top collaborators of Debby den Uyl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debby den Uyl. Debby den Uyl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wee, Marieke M. ter, Debby den Uyl, Michael T. Nurmohamed, et al.. (2021). Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial. Osteoporosis International. 32(7). 1441–1449.
2.
Boers, Maarten, Debby den Uyl, JWR Twisk, et al.. (2019). Predictors of sick leave and improved worker productivity after 52 weeks of intensive treatment in patients with early rheumatoid arthritis. Scandinavian Journal of Rheumatology. 48(4). 271–278.
3.
Wee, Marieke M. ter, Veerle M.H. Coupé, Debby den Uyl, et al.. (2017). Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial. RMD Open. 3(2). e000502–e000502.
4.
Tuyl, L. van, Maarten Boers, Debby den Uyl, et al.. (2017). Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. Lara D. Veeken. 56(9). 1586–1596.
5.
Tuyl, L. van, Maarten Boers, Peter M. van de Ven, et al.. (2016). The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis. Lara D. Veeken. 55(9). 1615–1622.
6.
Tuyl, L. van, Maarten Boers, Debby den Uyl, et al.. (2016). Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?. Arthritis Care & Research. 69(7). 989–996.
7.
Uyl, Debby den, Natasja M. van Schoor, Nathalie Bravenboer, Paul Lips, & Willem F. Lems. (2015). Low grade inflammation is associated with lower velocity of sound and broadband ultrasound attenuation in older men, but not with bone loss or fracture risk in a longitudinal aging study. Bone. 81. 270–276.
8.
Gent, Yoony Y. J., Marieke M. ter Wee, Alexandre E. Voskuyl, et al.. (2015). Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study. Arthritis Research & Therapy. 17(1). 266–266.
9.
Wee, Marieke M. ter, Debby den Uyl, Maarten Boers, et al.. (2014). Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. Annals of the Rheumatic Diseases. 74(6). 1233–1240.
10.
Uyl, Debby den, Marieke M. ter Wee, Maarten Boers, et al.. (2013). A non-inferiority trial of an attenuated combination strategy (‘COBRA-light‘) compared to the original COBRA strategy: clinical results after 26 weeks. Annals of the Rheumatic Diseases. 73(6). 1071–1078.
11.
Verbrugge, Sue Ellen, Yehuda G. Assaraf, Ben A. C. Dijkmans, et al.. (2012). Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis. Journal of Pharmacology and Experimental Therapeutics. 341(1). 174–182.
12.
Stuijver, Danka J. F., Debby den Uyl, Bregje van Zaane, et al.. (2012). FRI0114 The effect of combination therapy and prednisolone on haemostatic markers in rheumatoid arthritis: The cobra-light study. Annals of the Rheumatic Diseases. 71. 348–349.
13.
Uyl, Debby den, Marieke M. ter Wee, Maarten Boers, et al.. (2012). OP0151 Cobra-light therapy is clinically non-inferior to original cobra therapy in the treatment of early rheumatoid arthritis. Annals of the Rheumatic Diseases. 71. 104–105.
14.
Uyl, Debby den, Michael T. Nurmohamed, L. van Tuyl, Hennie G. Raterman, & Willem F. Lems. (2011). (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Research & Therapy. 13(1). R5–R5.
15.
Hoes, Jos N., Marlies C. van der Goes, Daniël H. van Raalte, et al.. (2011). Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Annals of the Rheumatic Diseases. 70(11). 1887–1894.
16.
Uyl, Debby den, Irene E. M. Bultink, & Willem F. Lems. (2011). Advances in Glucocorticoid-Induced Osteoporosis. Current Rheumatology Reports. 13(3). 233–240.
17.
Uyl, Debby den, Daniël H. van Raalte, Michael T. Nurmohamed, et al.. (2011). Metabolic effects of high‐dose prednisolone treatment in early rheumatoid arthritis: Balance between diabetogenic effects and inflammation reduction. Arthritis & Rheumatism. 64(3). 639–646.
18.
Uyl, Debby den, et al.. (2009). Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial. Clinical Rheumatology. 29(5). 465–472.
19.
Uyl, Debby den, Irene E. M. Bultink, & Willem F. Lems. (2004). Glucocorticoid-induced osteoporosis. PubMed. 29(5 Suppl 68). 109–130.
20.
Uyl, Debby den, Irene E. van der Horst‐Bruinsma, & Michiel A. van Agtmael. (2004). Progression of HIV to AIDS: a protective role for HLA-B27?. PubMed. 6(2). 89–96.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by A. Krabben Breakdown of academic impact, for papers by Chung‐Yuan Hsu Breakdown of academic impact, for papers by Takeshi Nakatsue Breakdown of academic impact, for papers by E. K. Li Breakdown of academic impact, for papers by Laurence Lutteri Breakdown of academic impact, for papers by Gaël Mouterde Breakdown of academic impact, for papers by Predrag Musikic Breakdown of academic impact, for papers by Giusy Peluso Breakdown of academic impact, for papers by Akinari Sekine Breakdown of academic impact, for papers by Šárka Forejtová